Specialists have identified possible useful predictors of improved motor function in presymptomatic infants with spinal muscular atrophy (SMA) treated with nusinersen, following an interim analysis of study data.
Specialists have identified possible useful predictors of improved motor function in presymptomatic infants with spinal muscular atrophy (SMA) treated with nusinersen, following an interim analysis of study data.